LABORATORIOS SAVAL

Select Your Country

Products Finder

TRUXIMA

Rituximab

Composition

Each mL of concentrate contains 10 mg of rituximab.

Each vial of 50 mL contains 500 mg of rituximab.
Each vial of 10 mL contains 100 mg of rituximab.

Presentations

- Truxima 500 mg concentrate for solution for infusion: Pack of 1 vial 
- Truxima 100 mg concentrate for solution for infusion: Pack of 2 vials

 

Indications

The registered formulation of Rituximab is 10mg/ml concentrate for solution for intravenous (IV) infusion, and it is indicated for:

• Non-Hodgkin’s Lymphoma (NHL): Rituximab is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma (FL) along with chemotherapy or in patients who are chemo-resistant or are in their second and subsequent relapse after  chemotherapy. It is also given in patients with CD20 positive large B cell NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisolone chemotherapy. Additionally, maintenance therapy is indicated for the treatment of FL individuals responding to induction therapy.
• Chronic Lymphocytic Leukaemia (CLL): Rituximab is indicated for the  treatment of patients with previously untreated and relapsed CLL in combination with chemotherapy.
• Rheumatoid Arthritis (RA): Rituximab in combination with methotrexate is given to the adult patient with severe active RA who had insufficient response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor inhibitor (TNFi) therapies.
• Granulomatosis with Polyangiitis and Microscopic Polyangiitis (GPA/MPA): In combination with glucocorticoids, Rituximab is given for the induction of remission in adult patients with severe, active GPA/MPA.